Skip to content

Education on BDNF on Pain Levels

Effect of Therapeutic Education on Pain Intensity and BDNF Levels in Patients With Chronic Pain

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05623579
Enrollment
66
Registered
2022-11-21
Start date
2023-10-01
Completion date
2025-05-28
Last updated
2023-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Musculoskeletal Pain

Keywords

BDNF, Pain Neuroscience Education, Exercise

Brief summary

The promotion of neuroplasticity in conjunction with strategies for restructuring maladaptive cognitions that largely cause the activation of neural networks that contribute to the perpetuation of pain is therefore a fundamental neurophysiological principle for establishing a neurophysiological basis for pain. perpetuation of pain, is therefore a fundamental neurophysiological principle for establishing physiotherapy therapeutic to establish therapeutic strategies from physiotherapy that contribute to improve the quality of life of patients with chronic pain. patients with chronic pain. Based on the theory that neurotrophic factors such as BDNF play a fundamental role in the initiation and or maintenance of hyperexcitability of central neurons in pain, we consider that the levels of this neurotrophic factor, such as BDNF, may have an important role in the perpetuation of pain. that the levels of this neurotrophic factor may be modified by the application of a therapeutic education protocol, favoring therapeutic education protocol, favoring a reduction in pain intensity.

Interventions

BEHAVIORALPain Neuroscience Education

8 Sessions of different pain education interventions

BEHAVIORALExercise

12 Sessions of Aerobic Exercise

Sponsors

Universidad Rey Juan Carlos
CollaboratorOTHER
Universidad Autonoma de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* males and females aged 18 to 65 years with musculoskeletal pain for a minimum of 3 months * patients recruited by information pamphlets from the university clinic of the Rey Juan Carlos University, and CSEU La Salle * not having received physiotherapy treatment for this same process in the last 3 months. * ability to perform all the clinical tests and to understand the study process, as well as to obtain informed consent.

Exclusion criteria

\- Systemic, neurological, oncological or inflammatory diseases; psychiatric pathologies, pregnancy, type II diabetes.

Design outcomes

Primary

MeasureTime frameDescription
Pain Intensity36 weeksPain intensity assessed with the 100 mm Visual Analog Scale, in which the patient is asked about his or her pain level at that moment, with one side being no pain and the other extreme being the worst pain imaginable.

Secondary

MeasureTime frameDescription
Anxiety and Depression (HADS)36 weeksAnxiety and depression will be assessed using the Spanish validated version of the HADS. The HADS is a self-administered measure with 14 items in total that ask the client to reflect on their mood in the past week. Seven items assess depression, 5 of which are markers for anhedonia (an inability to experience pleasure), and 2 concern appearance and feelings of slowing down. Seven items assess anxiety, of which 2 assess autonomic anxiety (panic and butterflies in the stomach), and the remaining 5 assess tension and restlessness (Dunbar, Ford, Hunt, & Der, 2000).
Quality of life (EQ-5D)36 weeksThe EQ-5D is a generic HRQoL. HRQoL that can be used both in relatively healthy individuals (general population) and in groups of patients with different pathologies. The individual assesses his or her own health status, first in levels of severity by dimensions and then on a more general visual analog scale (VAS).The third element of the EQ-5D is the index of social values that is obtained for each health state generated by the instrument. In this part of the questionnaire, the individual must mark the level of severity corresponding to his or her health status in each of the dimensions health status in each of the dimensions, referring to the same day on which the same day the questionnaire is completed.
Pain Catastrophism (PCS)36 weeksPain Catastrophism will be measured with the Spanish version of the Pain Catastrophism Scale. The Pain Catastrophizing Scale (PCS) is a 13-item self-report questionnaire considered to be the most frequent and extensively studied tool to assess pain catastrophizing for chronic pain. Good levels of content and construct validity, internal consistency and test-retest reliability of the PCS have been reported in studies examining different musculoskeletal disorders and different language versions.
BDNF level36 weeksBDNF level measured in blood serum by ELISA kit at baseline and at the end of the intervention.
Oxygen Saturation (SpO2)36 weeksmeasured with a finger pulse oximeter: A normal ABG oxygen level for healthy lungs falls between 80 and 100 millimeters of mercury (mm Hg).
Heart rate (HR)36 weeksmeasured with a finger pulse oximeter: A normal Heart Rate is between 60 and 120 pulse per minute.
Pain Severity Level (GCPS-R)36 weeksPain severity will be measured Chronic Pain Grading Scale Description: A measure of pain intensity and interference with normal daily activities. Format: 7 items Scoring: Scores for 6 of the items range from 0 (no pain) to 10 (pain as bad as it could be). The one remaining item requires filling in the number of days that pain has kept respondents from their typical activities. Scores classify respondents into one of 4 levels of pain intensity and activity interference: Low disability and low pain intensity Low disability and high pain intensity High disability and moderate limitation of activities High disability and severe limitation of activities

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026